SC News and Research

Medical practitioners talking to each other

NICHQ Webinar: Appointment Attendance

Increasing Appointment Attendance: A Vital Opportunity to Improve Health Outcomes for Those Living with Sickle Cell Diseases August 10, 2020, 3:30 – 4:30 p.m. ET To make health outcomes better, national rules for routine follow-up appointment every six months. More often for patients on specific drugs or having probelms. Yet, a 2019 national study showed that

NICHQ Webinar: Appointment Attendance Read More »

Emergency Care is Not Ideal for SC Patients

Study Finds Emergency Care is Not Ideal Most people with sickle cell disease (SCD) in the U.S. are happy with their PCPs, but less so with emergency care given at a hospital to manage severe pain, according to a survey of more than 400 teenage and adult patients. How a person expects to be treated

Emergency Care is Not Ideal for SC Patients Read More »

SCDC Webinar: Unite Sickle Cell

Sickle Cell Data Collection Program “Unite Sickle Cell: Collaboration and Community in Sickle Cell” Wednesday, September 18, 2019 1:30 – 3:00 PM PDT Register now:  https://attendee.gotowebinar.com/register/2843093377260613389   Presented by Dr. Nik Rashid and Ms. Linetta Barnes from Nevada and Ms. Mary Brown and Ms. Jennifer Fields from the Sickle Cell Disease Foundation of California. Tracking California’s

SCDC Webinar: Unite Sickle Cell Read More »

WEBINAR SERIES Sickle Cell Science: Path to Progress

WEBINAR SERIES Sickle Cell Science: Path to Progress To commemorate Sickle Cell Awareness Month 2019, this September the National Heart, Lung, and Blood Institute (NHLBI) and partner agencies and institutions will host Sickle Cell Science: Path to Progress, a four-part webinar series that will discuss genetic therapies, progress in pain management, bone marrow transplants and other therapies, and

WEBINAR SERIES Sickle Cell Science: Path to Progress Read More »

GBT Announces Updated 24-Week Efficacy Data

All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor Global Blood Therapeutics, Inc. (GBT) today announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease (SCD). The findings from 274 adolescents and adults treated with

GBT Announces Updated 24-Week Efficacy Data Read More »

Shopping Cart
Scroll to Top
Secret Link